From the Journals

Can SGLT-2 Inhibitors Shield Against Autoimmune Disease?

Researchers found sodium-glucose cotransporter-2 inhibitors lowered autoimmune rheumatic disease risk by 11% in adults with type 2 diabetes.

Share

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors in adults with type 2 diabetes were linked to a lower incidence of autoimmune rheumatic diseases compared to sulfonylureas, according to a BMJ study. Analyzing over 2 million individuals from South Korea, researchers found a hazard ratio of 0.89 for developing these diseases, particularly due to a decreased risk of inflammatory arthritis. The study controls for confounders and highlights the potential of newer diabetes medications to influence autoimmune outcomes.

Original Source(s)

Can SGLT-2 Inhibitors Shield Against Autoimmune Disease?

Researchers found sodium-glucose cotransporter-2 inhibitors lowered autoimmune rheumatic disease risk by 11% in adults with type 2 diabetes.

  • by Kathryn Wighton

  • October 29, 2025

  • 2 min

Related Content

Plozasiran Wins FDA Nod for FCS

Arrowhead’s small interfering RNA therapy reduced triglycerides and lowered pancreatitis risk in the phase 3 PALISADE trial, providing a quarterly self-administered option for patients with familial chylomicronemia syndrome.

Waist Circumference Link to DR

Obesity measure linked to diabetic retinopathy risk in US adults

Testing Metformin’s Reach in PAD

Double-blind trial of 202 patients shows no improvement in 6-minute walk distance at 6 months compared with placebo.